Distribution of Streptococcus pneumoniae serotypes and serogroups among patients with invasive pneumococcal diseases in the Czech Republic in 1996-2003: Background data for vaccination strategy;Distribuce sérotypů a séroskupin Streptococcus pneumoniae u pacientů s invazivními pneumokokovými onemocněními v České republice v letech 1996-2003: Podklady pro vakcinční strategii

Epidemiologie, Mikrobiologie, Imunologie

Volumn 54, Issue 1, 2005, Pages 3-10

  Motlová, Jitka ^a  

^a Statni Zdravotni Ustav   (Czech Republic)

Author keywords

Conjugated pneumococcal vaccine; Infections; Pneumococci; Serogroups; Serotypes

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONTROLLED STUDY; CZECH REPUBLIC; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; POPULATION DISTRIBUTION; SEROTYPE; SPUTUM ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

CHILD, PRESCHOOL; CZECH REPUBLIC; HUMANS; INFANT; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 14044266898     PISSN: 12107913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Advisory Committee on Immunization Practices. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage. MMWR Morb. Mortal. Wkly Rep., 2001, 50, s. 1140-1142.
2. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendation for the prevention of pneumococcal conjugate vaccine, and antibiotic prophylaxis. Pediatrics, 2000, 106, s. 362-366.
3. Austrian, R. The quellung reaction, a neglected microbiologic technique. Mt. Sinai J. Med., 1976, 43, s. 699-709.
4. Black, S. S., Shinefield, H. R., Fireman, B. et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J., 2000, 19, s. 187-195.
5. Buchholz, U., Bronzwaer, S. L. A. M., Schrijnemakerts, P. et al. and the EARSS participants. EARSS activities and results: update. Eurosurveillance, 2001, 6, s. 2-5.
6. Center for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep., 2000, 49, s. 1-38.
7. Douglas, R. M., Paton, J. C., Duncan, S. J. et al. Anti-body response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis., 1983, 148, s. 131-137.
8. Feikin, D. R., Klugman, K. P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis., 2002, 35, s. 547-555.
9. Hausdorff, W. P., Bryant, J., Paradiso, P. R. et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis., 2000, 30, s. 100-121.
10. Hsueh, P. R., Wu, J. J., Hsiue, T. R. Invasive Streptococcus pneumoniae infection associated with rapidly fatal outcome in Taiwan. J. Formos. Med. Assoc., 1996, 95, s. 364-371.
11. Jodár, L., Butler, J., Carlone, G. et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine, 2003, 21, s. 3265-3272.
12. Konradsen, H. B., Kaltoft, M. S. Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance. Clin. Diagn. Lab. Immunol., 2002, 9, s. 358-365.
13. Kyaw, M. H., Jones, I. G., Campbell, H. et al. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health. Acta Pediatr., 2001, 90, s. 473-476.
14. Lawrenson, J. B., Klugman, K. P., Eidelman, A. et al. Fatal infection cause by multiply resistant type 3 pneumococcus. J. Clin. Microbiol., 1988, 26, s. 1590-1591.
15. Motlová, J.: Distribuce sérotypů Streptococcus pneumoniae v České republice, duben 1995 - prosinec 1998. Podklady pro použití typově specifické pneumokokové vakcíny. Klin. Mikrobiol. Inf. Lék., 1999, 2-3, s. 65-72.
16. Mufson, M. A., Kruss, D. M., Wasil, R. E. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch. Intern. Med., 1974, 134, s. 505-510.
17. Nielsen, S. V., Henrichsen, J. Capsular types of Streptococcus pneumoniae isolated from blood and CSF during 1982-1987. Clin. Infect. Dis., 1992, 15, s. 794-798.
18. Normark, B. H., Ortoqvist, A., Kalin, M. et al. Changes in serotype distribution may hamper efficacy of pneumococcal conjugate vaccines in children. Scand. J. Infect. Dis. 2001, 33, s. 848-850.
19. Obaro, S. K., Adegbola, R. A. The pneumococcus: carriage, disease and conjugate vaccines. J. Med. Microbiol., 2002, 51, s. 98-104.
20. Overweg, K., Bogaert, D., Sluijter, M. et al. Genetic relatedness within serotypes of penicilin-susceptible Streptococcus pneumoniae isolates. J. Clin. Microbiol., 2000, 38, s. 4548-4553.
21. Pelton, S. I., Dagan, R., Gaines, B. M. et al. Pneumococcal conjugate vaccines: proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine, 2003, 21, s. 1562-1571.
22. Reinert, R. R., Kaufhold, A., Schlaeger, J. J. et al. Serotype distribution and antibiotic susceptibility of Streptococcus pneumoniae isolates causing systemic infections among children in Germany, 1992 to 1996. Pediatr. Infect. Dis. J., 1997, 16, s. 244-245.
23. Richter, S. S., Heilmann, K. P., Coffmann, S. L. et al. The molecular epidemiology of penicilin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin. Infect. Dis., 2002, 34, s. 330-339.
24. Robbins, J. B., Austrian, R., Lee, C. J. et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine, with emphasis on the cross-reactive types within groups. J. Infect. Dis., 1983, 148, s. 1136-1159.
25. Schinefield, H. R., Black, S. S., Lewis, E. M. et al. Efficacy and safety of pneumococcal conjugate vaccine in large scale filed trials. Pediatr. Infect. Dis., 2000, 19, s. 394-397.
26. Scott, J. A. G., Hall, A: J., Dagan, R. et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: association with age, sex, and geografy in 7,000 episodes of invasive disease. Clin. Infect. Dis. 1996, 22, s. 973-981.
27. Skoczyñska, A., Hryniewicz, W. Genetic reladness, antibiotic susceptibility, and serotype distribution od Streptococcus pneumoniae responsible for meningitis in Poland, 1997-2001. Microbial Drug Resist., 2003, 9, s. 175-181.
28. Urbášková, P., Motlová, J., Žemličková, H. Antibiotická rezistence invazivních pneumokoků a jejich sérotypy v České republice. Čas. Lék. čes., 2004, 3, s. 178-183.
29. www.earss.rivm.nl